Wednesday, August 31, 2022 4:49:24 PM
I believe you underestimate the hurdles with ROW RAs, government bureaucracy, red tapes, price sensitivity, cloud of internal major pharma groups, local manufacturing requirements, scalability, etc. I live and breathe this world so I speak from direct experience.
Dr. Pazdur has literally no say in how countries like China, India, etc run their health economics, RA, processes, etc. These red tapes and hurdles won’t magically disappear because FDA or MHRA approved the vaccine as SOC for nGBM & rGBM. Hence, it simply doesn’t make sense for NWBO to fight that battle for a very small fraction of population in each region that can afford such treatment. These few wealthy folks will flock to US or UK anyway! It’s unfortunate but that’s the reality on the ground.
Anyway, you are welcome to stick with your theory.
Dr. Pazdur has literally no say in how countries like China, India, etc run their health economics, RA, processes, etc. These red tapes and hurdles won’t magically disappear because FDA or MHRA approved the vaccine as SOC for nGBM & rGBM. Hence, it simply doesn’t make sense for NWBO to fight that battle for a very small fraction of population in each region that can afford such treatment. These few wealthy folks will flock to US or UK anyway! It’s unfortunate but that’s the reality on the ground.
Anyway, you are welcome to stick with your theory.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
